Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammation and neuro-oncology. The therapies are based on hydroxyl dendrimers (HDs), a targeted platform technology exclusively licensed from firm founders, Kannan Rangaramanujam and Sujatha Kannan at Johns Hopkins University.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/28/22 | $69,000,000 | Series B |
Huadong Medicine Investment Holding Co. Natural Capital Plum Alley Investments Tribe Capital | undisclosed |
